Acute Myeloid Leukemia (AML) Clinical Trial
Official title:
Venetoclax (Venclexta Tablet) Post-Marketing Surveillance for AML Patients
NCT number | NCT04826523 |
Other study ID # | P20-444 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | April 5, 2021 |
Est. completion date | November 30, 2025 |
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective oral venetoclax is in participants with AML . Adverse events and change in disease activity will be monitored under routine clinical practice. Venetoclax is an approved drug for treatment of Acute Myeloid Leukemia (AML). Around 600 participants of age 19 years and above will be enrolled in the study in multiple medical institutions across South Korea. Participants will receive oral venetoclax tablets as prescribed by their physician in the routine clinical practice. Participants will be observed for 7 cycles ( each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Status | Recruiting |
Enrollment | 600 |
Est. completion date | November 30, 2025 |
Est. primary completion date | November 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years and older |
Eligibility | Inclusion Criteria: --Acute Myeloid Leukemia (AML) participants who have been prescribed oral Venetoclax tablets for the first time according to the approved label. Exclusion Criteria: - Participants with contraindications to Venetoclax as listed on the approved local label. - Participants receiving Venetoclax in clinical trials. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Kyungpook National University Hospital /ID# 257398 | ?? | Daegu Gwang Yeogsi |
Korea, Republic of | Kosin University Gospel Hospital /ID# 257399 | Busan | Busan Gwang Yeogsi |
Korea, Republic of | Pusan National University Hospital /ID# 239010 | Busan | |
Korea, Republic of | Yeungnam University Medical Center /ID# 239007 | Daegu | |
Korea, Republic of | Chonnam National University Hwasun Hospital /ID# 257478 | Hwasun-gun | Jeonranamdo |
Korea, Republic of | Gachon University Gil Medical Center /ID# 239008 | Incheon | Gyeonggido |
Korea, Republic of | Korea University Anam Hospital /ID# 231022 | Seoul | |
Korea, Republic of | Samsung Medical Center /ID# 239009 | Seoul | |
Korea, Republic of | Seoul National University Hospital /ID# 257477 | Seoul | |
Korea, Republic of | Yonsei University Health System Severance Hospital /ID# 239006 | Seoul | Seoul Teugbyeolsi |
Lead Sponsor | Collaborator |
---|---|
AbbVie |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants Who Reported Serious Adverse Event/Drug Reaction | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. Treatment-emergent adverse events/treatment-emergent serious adverse events (TEAEs/TESAEs) are defined as any event that began or worsened in severity on or after the first dose of study drug. | 32 weeks | |
Secondary | Percentage of Participants who Achieved Complete Remission (CR) | The percentage of participants with complete remission (CR) will be calculated based on the modified International Working Group (IWG) criteria for AML. | 28 weeks | |
Secondary | Percentage of Participants who Achieved Complete Remission With Incomplete Hematologic Recovery (CRi) | Incomplete regeneration of bone marrow (CRi) as defined in the study protocol. | 28 weeks | |
Secondary | The Percentage of Participants who Achieved Composite Complete Remission (CR+CRi) | Composite Complete Remission (CRc) is defined as Complete Remission (CR) + CRi (CR with incomplete blood count recovery) based on protocol. | 28 weeks | |
Secondary | Median Time to Achieve Complete Remission [CR] (month) | Time from date of first oral Venetoclax intake and the date of the assessment having documented Complete Remission (in months). | 28 weeks | |
Secondary | Median Time to Achieve CRi | Time from the date of first oral venetoclax intake and the date of the assessment having documented Complete Remission with incomplete Hematologic recovery (CRi). | 28 weeks | |
Secondary | Median Overall Survival [OS] (month) | Time from the date of first oral venetoclax intake to the date of death from any cause. | 28 weeks | |
Secondary | Median Progression Free Survival [PFS] (month) | Median time to achieve Progression Free Survival (PFS) which is the time from [enrollment or randomization or first dose] to disease progression or death [to the first occurrence of radiographic progression determined by blinded independent central review or death from any cause], whichever occurs first. | 28 weeks | |
Secondary | Overall Response Rate (ORR) Based on Effectiveness Outcome | Overall Response Rate (ORR) is the proportion of the responders to the total number of participants. | 28 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04240002 -
A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1/Phase 2 | |
Completed |
NCT02626715 -
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
|
Phase 2 | |
Completed |
NCT05488613 -
Healthcare Resource Utilization in Adults Diagnosed With Acute Myeloid Leukemia (AML)
|
||
Completed |
NCT02265731 -
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT02927938 -
Leukemia Stem Cell Detection in Acute Myeloid Leukemia
|
Phase 3 | |
Completed |
NCT01772953 -
Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
|
Phase 2 | |
Recruiting |
NCT03188874 -
Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
|
||
Completed |
NCT00071006 -
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
Completed |
NCT04079296 -
A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS)
|
Phase 1/Phase 2 | |
Completed |
NCT04509622 -
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
|
Phase 3 | |
Withdrawn |
NCT03699384 -
Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT03613532 -
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
|
Phase 1 | |
Completed |
NCT02252107 -
10-day Decitabine, Fludarabine and 2 Gray TBI as Conditioning Strategy for Poor and Very Poor Risk AML in CR1
|
Phase 2 | |
Terminated |
NCT02259348 -
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
|
Phase 2 | |
Terminated |
NCT01463410 -
Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler
|
N/A | |
Completed |
NCT01242774 -
Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Terminated |
NCT02134782 -
Yoga Fatigue Study
|
N/A | |
Completed |
NCT01685619 -
AML-MDS Novel Prognostic Tests Clinical Study
|
||
Completed |
NCT03625505 -
A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT04266795 -
A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy
|
Phase 2 |